会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • Method for identifying Alzheimer's disease therapeutics using transgenic animal models
    • 使用转基因动物模型鉴定阿尔茨海默病治疗剂的方法
    • US20040226054A1
    • 2004-11-11
    • US10746473
    • 2003-12-23
    • Kate Dora GamesDale Bernard SchenkLisa Claire McConloguePeter Andrew SeubertRussell E. Rydel
    • A01K067/00
    • C07K14/4711A01K67/0275A01K67/0276A01K67/0278A01K2207/15A01K2217/00A01K2217/05A01K2217/075A01K2227/00A01K2267/0312A01K2267/0356C07K2319/02C12N15/8509
    • The construction of transgenic animal models of human Alzheimer'disease, and methods of using the models to screen potential Alzheimer's disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the null-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the Anull region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, null-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.
    • 描述了人类阿尔茨海默病的转基因动物模型的构建以及使用该模型筛选潜在的阿尔茨海默病治疗剂的方法。 基于所有三种形式的β-淀粉样蛋白前体蛋白(APP),APP695,APP751和APP770的表达以及基于天然存在的突变的各种点突变,模型的特征在于类似于在阿尔茨海默病中观察到的病理学的病理学 ,例如氨基酸717处的伦敦和印第安纳家族性阿尔茨海默病(FAD)突变,APP基因中预测的突变和含有Abeta区的APP的截短形式。 可以从转基因动物中分离动物细胞,或者使用具有标准技术如脂质转染或电穿孔的相同构建体来制备动物细胞。 转基因动物或动物细胞用于筛选改变阿尔茨海默氏病病理过程的化合物,如通过其对动物中APP,β-淀粉样蛋白肽和许多其他阿尔茨海默氏病标志物的量的影响所测量的,神经病理学 动物,以及动物的行为改变。
    • 6. 发明授权
    • Transgenic reptiles
    • 转基因爬行动物
    • US08134044B2
    • 2012-03-13
    • US12641847
    • 2009-12-18
    • Paul E. MozdziakJames N. Petitte
    • Paul E. MozdziakJames N. Petitte
    • A01K67/033C12N15/00G01N33/00C12P21/00
    • A01K67/0275A01K2217/05A01K2227/00A01K2267/03C12N15/8509C12N2799/027
    • A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal comprises cells containing a sequence encoding the heterologous expression product. The sequence encoding the heterologous expression product is integrated into the genome of the animal (e.g., in some or all cells thereof, and in some embodiments into germ cells thereof). The sequence encoding the heterologous expression product is, in general, operatively associated with an expression sequence or promoter. The animals are useful for, among other things, testing of repellents, testing of toxicological compounds, as teaching aids, for venom production, etc.
    • 描述了表达异源表达产物的转基因动物如转基因蛇或其他爬行动物及其制备方法。 通常,动物包含含有编码异源表达产物的序列的细胞。 编码异源表达产物的序列整合到动物的基因组中(例如,在其一些或所有细胞中,并且在一些实施方案中整合到其生殖细胞中)。 编码异源表达产物的序列通常与表达序列或启动子可操作地相关联。 这些动物除了别的以外,对于驱虫剂的测试,毒理化合物的测试,作为助剂,用于毒液的生产等是有用的。